Literature DB >> 29404396

Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells".

Lucie de Beauchamp1, Pablo Baquero1, Elodie M Kuntz2, Eyal Gottlieb2,3, G Vignir Helgason1.   

Abstract

We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.

Entities:  

Keywords:  CML; Cancer stem cells; Imatinib; Leukaemia; Metabolism; OXPHOS; TCA cycle; Tigecycline; Tyrosine kinase inhibitor

Year:  2017        PMID： 29404396      PMCID： PMC5791851          DOI： 10.1080/23723556.2017.1403532

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.

Authors:  Alice Giustacchini; Supat Thongjuea; Nikolaos Barkas; Petter S Woll; Benjamin J Povinelli; Christopher A G Booth; Paul Sopp; Ruggiero Norfo; Alba Rodriguez-Meira; Neil Ashley; Lauren Jamieson; Paresh Vyas; Kristina Anderson; Åsa Segerstolpe; Hong Qian; Ulla Olsson-Strömberg; Satu Mustjoki; Rickard Sandberg; Sten Eirik W Jacobsen; Adam J Mead
Journal:  Nat Med       Date:  2017-05-15       Impact factor: 53.440

2.  Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.

Authors:  Elisabeth Bolton-Gillespie; Mirle Schemionek; Hans-Ulrich Klein; Sylwia Flis; Grazyna Hoser; Thoralf Lange; Margaret Nieborowska-Skorska; Jacqueline Maier; Linda Kerstiens; Mateusz Koptyra; Martin C Müller; Hardik Modi; Tomasz Stoklosa; Ilona Seferynska; Ravi Bhatia; Tessa L Holyoake; Steffen Koschmieder; Tomasz Skorski
Journal:  Blood       Date:  2013-03-29       Impact factor: 22.113

3.  Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.

Authors:  Marko Skrtić; Shrivani Sriskanthadevan; Bozhena Jhas; Marinella Gebbia; Xiaoming Wang; Zezhou Wang; Rose Hurren; Yulia Jitkova; Marcela Gronda; Neil Maclean; Courteney K Lai; Yanina Eberhard; Justyna Bartoszko; Paul Spagnuolo; Angela C Rutledge; Alessandro Datti; Troy Ketela; Jason Moffat; Brian H Robinson; Jessie H Cameron; Jeffery Wrana; Connie J Eaves; Mark D Minden; Jean C Y Wang; John E Dick; Keith Humphries; Corey Nislow; Guri Giaever; Aaron D Schimmer
Journal:  Cancer Cell       Date:  2011-11-15       Impact factor: 31.743

4.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Authors:  Eleni D Lagadinou; Alexander Sach; Kevin Callahan; Randall M Rossi; Sarah J Neering; Mohammad Minhajuddin; John M Ashton; Shanshan Pei; Valerie Grose; Kristen M O'Dwyer; Jane L Liesveld; Paul S Brookes; Michael W Becker; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

5.  Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.

Authors:  Stéphane Prost; Francis Relouzat; Marc Spentchian; Yasmine Ouzegdouh; Joseph Saliba; Gérald Massonnet; Jean-Paul Beressi; Els Verhoeyen; Victoria Raggueneau; Benjamin Maneglier; Sylvie Castaigne; Christine Chomienne; Stany Chrétien; Philippe Rousselot; Philippe Leboulch
Journal:  Nature       Date:  2015-09-02       Impact factor: 49.962

6.  Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.

Authors:  Mary T Scott; Koorosh Korfi; Peter Saffrey; Lisa E M Hopcroft; Ross Kinstrie; Francesca Pellicano; Carla Guenther; Paolo Gallipoli; Michelle Cruz; Karen Dunn; Heather G Jorgensen; Jennifer E Cassels; Ashley Hamilton; Andrew Crossan; Amy Sinclair; Tessa L Holyoake; David Vetrie
Journal:  Cancer Discov       Date:  2016-09-14       Impact factor: 39.397

7.  A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.

Authors:  Gregory A Reed; Gary J Schiller; Suman Kambhampati; Martin S Tallman; Dan Douer; Mark D Minden; Karen W Yee; Vikas Gupta; Joseph Brandwein; Yulia Jitkova; Marcela Gronda; Rose Hurren; Aisha Shamas-Din; Andre C Schuh; Aaron D Schimmer
Journal:  Cancer Med       Date:  2016-10-13       Impact factor: 4.452

Review 8.  The chronic myeloid leukemia stem cell: stemming the tide of persistence.

Authors:  Tessa L Holyoake; David Vetrie
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

9.  Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.

Authors:  Sheela A Abraham; Lisa E M Hopcroft; Emma Carrick; Mark E Drotar; Karen Dunn; Andrew J K Williamson; Koorosh Korfi; Pablo Baquero; Laura E Park; Mary T Scott; Francesca Pellicano; Andrew Pierce; Mhairi Copland; Craig Nourse; Sean M Grimmond; David Vetrie; Anthony D Whetton; Tessa L Holyoake
Journal:  Nature       Date:  2016-06-08       Impact factor: 49.962

10.  Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.

Authors:  Elodie M Kuntz; Pablo Baquero; Alison M Michie; Karen Dunn; Saverio Tardito; Tessa L Holyoake; G Vignir Helgason; Eyal Gottlieb
Journal:  Nat Med       Date:  2017-09-18       Impact factor: 53.440
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.